Cardiac dysfunction in the trastuzumab clinical trials experience Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Paclitaxel

abstract

  • Trastuzumab is associated with an increased risk of CD, which is greatest in patients receiving concurrent anthracyclines. In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab.

publication date

  • March 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1200/JCO.20.5.1215

PubMed ID

  • 11870163

Additional Document Info

start page

  • 1215

end page

  • 21

volume

  • 20

number

  • 5